August 6, 2009 (FinancialWire) — Map Pharmaceuticals, Inc. (NASDAQ: MAPP) plans to offer 3.5 million shares of its common stock in a public offering. Deutsche Bank Securities (NYSE: DB) is acting as sole book-running manager.

The company plans to grant to the underwriters of the offering an option to purchase 500,000 additional shares of common stock to cover over-allotments.

Mountain View, California-based Map Pharmaceuticals develops and commercializes drug therapies. The company is developing Levadex inhaled therapy for the potential treatment of migraine and has reported positive results from the efficacy portion of the first Phase 3 trial of the drug.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.